African Pioneer Share Discussion Threads

[backmarker] 30/5/2008 00:00

there was a reasonably positive article on ASP in SHARES mag. today.

probably that which helped lift the share price

[backmarker] 21/5/2008 15:20

V6, very good point on e-p. I wonder why not.

[v6syncro] 16/5/2008 09:33

Bitter pill for Ascribe on e-prescribing

In the pharmacy systems categories, Ascribe missed out on the prescribing category, but was appointed in the stock control category, whilst JAC were appointed in both categories.

[v6syncro] 08/5/2008 10:12

Service Category 2.14 – ePrescribing Systems

In other categories there are some interesting names missing. Ascribe, for instance, does not appear in e-prescribing category!!!

Considering ePrescribing is a major play! Look forward to the comments

[backmarker] 08/5/2008 09:03

Ascribe wins 11 UK National Health Service contracts over 4 years

LONDON (Thomson Financial) - Ascribe Plc. said it has won 11 framework
contracts with the UK National Health Service to provide its Clinical
Information Technology services over a four-year period.
No financial details were disclosed.

[e-mail]
kkb/ak

[backmarker] 08/5/2008 09:02

This is an important development for Ascribe.

===================

RNS Number:9397T
Ascribe plc
08 May 2008

Press Release 8 May 2008


Ascribe plc

("Ascribe" or "the Group")


Award of eleven ASCC framework contracts


Ascribe plc (AIM:ASP), the innovative health IT group, today announces that it
has been successful in its bid to supply Clinical Information Technology (CIT)
services through the UK National Health Service's National Program for IT ASCC
('Additional Supply Capability and Capacity') Framework Agreement. This gives
the Group's customers the ability to order CIT services through a framework
agreement directly from Ascribe or through a number of partners, such as BT and
CSC, over a four year period.

Commenting on the ASCC, Stephen Critchlow, Executive Chairman of Ascribe, said:
"This is a great achievement and I am delighted to say that, between Ascribe and
our closest partners, the Group's products and services - including those from
our key markets, Accident and Emergency, hospital pharmacy, electronic
prescribing and mental health - are on the approved list. The ASCC Framework
Agreement adds another option to our English NHS customers for the procurement
of services and we look forward to the opportunity of supplying through this
route. The catalogue will provide local purchasers within the English NHS
greater autonomy to make healthcare IT decisions. Our order book has already
grown to record levels from local procurement outside of the National Program
and now that Ascribe has been included on the ASCC, we expect our order pipeline
to grow further still."

Ascribe is the market leader in Medicines Management IT, focussing on solutions
that directly improve clinical safety and patient care. Over 50% of UK
hospitals use the Group's pharmacy systems and it now offers solutions to over
25% of mental health departments and 30% of Accident and Emergency departments.
Furthermore, Ascribe's solutions are installed internationally in Australia, New
Zealand, Hong Kong, Republic of Ireland and Malaysia.

The ASCC can be used to support both National Programme for IT related work and
wider healthcare IT projects.

[backmarker] 13/3/2008 19:09

cnx,

having worked in healthcare IT myself until recently i can understand why SC is now using "expected" etc., much more.

a major problem in supplying IT to NHS units is that even when you have the order, the implementation can be delayed - by the NHS unit - repeatedly, and without warning. This means revenues - hence profit - being delayed also, and unexpectedly. Ascribe has a great order book, but the delivery of it will not be fully under its control.

ascribe's last 2 sets of figures have been somewhat behind expectations, for understandable reasons. - but still behind. so there is now pressure on this next half - which is the "bigger" half - for SC to deliver.

but the key to the ascribe share price really taking off is substantially increased revenue. that won't happen in the short-term from the NHS unless it really opens up the alternative supplier market (the LSP "monopolies" last another 5 years). and although overseas sales seem to be growing (Australia), that is going to be a long haul. that leaves acquisitions.

ascribe has had a steady trickle of these. i suspect a faster rate is inhibited by a lack of suitable candidates and i think SC is being very careful about the quality of what he buys.

where does that leave us ? imho with a solid company which will continue to grow steadily, and a good possibility that it could grow much faster.

[caradog] 13/3/2008 07:58

I note that the interim statement studiously ignored primary care (GP) systems. I was interested not as a shareholder, but as a customer. We are planning to change our system this year, from Exeter (Ascribe) to EMIS. I know of 4 practices that have already swapped from Exeter and 1 more that is planning to do so. I know of none that is planning to swap to Exeter. To me, Ascribe's system feels crude and unsophisticated. It cannot match the functionality of its larger competitors. I find it unstable - it throws me out several times a day. Changing systems is a lot of work but it will be worth it in the long run. I can't see Ascribe continuing with GP systems in the long run because I doubt if their apparently shrinking customer base will provide the revenues needed to match the investment their larger rivals are making in system funcionality. These observations are just my narrow personal view, but if I were a sharholder I would want to know how many GP systems are out there today compared with, say, 3 years ago.

[cnx] 13/3/2008 00:55

the interims seem a little cautious and a hint of uncertainty?
"Prospects

With 60-70% of our annual turnover coming from recurring maintenance contracts
our expected revenue growth in the remainder of this year will depend on the
delivery of our existing order book and of new orders that are expected in the
second half. We expect double-digit percentage revenue growth for the year to
June 2008 in comparison to 2007. This will be dependent on the continued sale
of licences to new and existing customers together with the associated
implementation revenues. We expect this new business to accrue across all our
departmental and enterprise-wide solutions."

"expected","depend","expected","expect","dependent","new","expect"..........not much cetainty in this short para.

[currypasty] 23/1/2008 07:54

Ascribe plc
23 January 2008


Press Release 23 January 2008


Ascribe plc
("Ascribe" or "the Group")

Trading Update

Ascribe plc (AIM:ASP), the International Health IT company, is pleased to
provide an update on current trading in advance of its interim results for the
six months ended 31 December 2007, to be announced on 12 March 2008. The Group
confirms that it is on track to meet market expectations for the full year.

The Group's order book of new sales has grown to a record level of £3.3M,
following a series of significant sales wins in December 2007 which includes a
major integrated order. The Board believes that increased demand in December
indicates the market as a whole is shifting to local level decision making. The
Board therefore expects the second half of the financial year to be strong as
the growing order book is delivered.

Commenting on recent trading, Stephen Critchlow, CEO of Ascribe said: "I am
delighted with the progress the Group has made in the first half of our
financial year. Ascribe has a reputation for delivering robust technology which
is critically focused on the needs of clinicians and their patients at the point
of care. The strength of our order book stems from the ever-increasing autonomy
of local purchasers within the NHS to make healthcare IT decisions."

[bbmc] 03/1/2008 15:21

not a holder but explains the rise.

[wjccghcc] 03/1/2008 08:37

Been a good opportunity to add around the 29-30p level though :-)

[currypasty] 03/1/2008 08:35

seller out, buyers return ????


about time, I hope it gets back to 65 as quick as it left it!

[currypasty] 07/12/2007 13:00

RNS Number:4417J
Ascribe plc
07 December 2007




Ascribe plc
(the "Company")

Holding in Company


The Company received notification on 6 December 2007 from Universities
Superannuation Scheme Ltd ("USS") that on 4 December 2007 USS had a notifiable
interest in the Company of 3,684,909 ordinary shares of 1p each in the Company,
representing 3.14 per cent. of the Company's current issued ordinary share
capital.

7 December 2007

[wjccghcc] 01/12/2007 09:55

Looks like there's a big seller out there.

[currypasty] 30/11/2007 15:22

26 - 28

what a disaster area, after 65p in the summer... is there a big pile of doo doo yet to be anounced... obviously something up!

[currypasty] 29/11/2007 12:56

RNS Number:7729I
Ascribe plc
29 November 2007




Ascribe plc
(the "Company")

Director Shareholding in Company


The Company was informed on 29 November 2007 that Ian Priestner and David
Hughes, both directors of the Company have purchased ordinary shares of 1p each
in the Company ("Ordinary Shares").

Ian Priestner purchased 29,972 Ordinary Shares at a price of 33p per share on 28
November 2007. Mr Priestner's interest following this purchase stands at 29,972
Ordinary Shares, which represents 0.026 per cent. of the Company's current
issued share capital.

David Hughes purchased 65,000 Ordinary Shares at prices between 30 and 30.5p on
28 and 29 November 2007. Mr Hughes's interest following this purchase stands at
415,000 Ordinary Shares, which represents 0.353 per cent. of the Company's
current issued share capital

[currypasty] 31/10/2007 11:49

RNS Number:7061G
Ascribe plc
31 October 2007


Press Release 31 October 2007

Ascribe plc
('Ascribe' or 'The Group')

AGM Statement



Ascribe plc ("AIM:ASP"), the health IT Group, announces that at the Group's
Annual General Meeting held today all resolutions put to Shareholders by the
Board were duly passed.



At the meeting, the Board of Ascribe also updated shareholders on the Group's
performance since its Final Results statement, as issued on Wednesday 19
September for the period ending 30 June 2007.



Speaking at the meeting, Stephen Critchlow, Executive Chairman, said "I am
delighted to report that the Group has made a positive start to the 2007/8
financial year. We have begun to see the receipt of orders that were delayed in
the 2007 financial year end and our trading performance in the first quarter is
in line with management expectations. In particular, I am pleased to report the
receipt of the Group's first Accident and Emergency order in the Australasia
market and our win of the Plymouth Pharmacy contract from our principal
competitor in that area. These examples illustrate both the market leading
quality of our products and the opportunities open to the Group by cross-selling
new products into an established market.



Ascribe recently acquired Scorpio Information Systems Ltd, which we expect to be
earnings-enhancing in this financial year. The Group looks forward to
integrating their solutions into our portfolio.



The Directors remain confident that the Group will continue to develop and
deliver clinician-focused IT systems across the complete Health IT market, and
will deliver a trading performance in line with expectations."

[currypasty] 22/10/2007 12:48

RNS Number:1231G
Ascribe plc
22 October 2007


Press Release 22 October 2007

Ascribe plc

("Ascribe" or "the Group")


Ascribe plc acquires Scorpio Information Systems Limited
enhancing portfolio of healthcare clinical information management systems



22 October 2007 - Ascribe plc (AIM:ASP), the health IT Group, today announces
that it has acquired Scorpio Information Systems Limited ("Scorpio"), a supplier
of clinical information management systems to the UK National Health Service ("
NHS"). Scorpio has developed over thirty clinical modules for hospital
departments and patient care; these include endoscopy reporting, maternity,
eye-unit casualty and oncology clinics, which are in use at twelve NHS
hospitals.

This acquisition enables Ascribe to expand its Group offering with a greater
range of comprehensive patient-centric information management systems, all of
which are capable of securely feeding information into patients' electronic
health records. The Ascribe Board expects to cross-sell Scorpio's systems to
other customers of the Group.

Scorpio will continue to develop clinician-focused modules that address the
healthcare IT requirements of modern hospitals. Scorpio's solutions are
underpinned by their ability to communicate health data efficiently and their
faithful adherence to consistent best practice in a healthcare environment -
from data collection through to the establishment of individual patient care
pathways. The additional resources of the Ascribe group will enable Scorpio to
extend its own suite of healthcare solutions.

The total consideration of #1.31m, including payment for approximately #600k
cash in Scorpio at completion, was satisfied by the payment of #0.88m cash and
by the issue of ordinary shares in Ascribe plc to the value of #0.43m. In its
last statutory accounts, Scorpio reported turnover of #0.52m and an operating
profit of #0.24m. The Board believes that this acquisition will be earnings
enhancing during the first year.

Stephen Critchlow, Executive Chairman of Ascribe commented, "I am delighted with
this acquisition; Ascribe and Scorpio share a fundamental approach towards
product development. We have both focused our software on improving patient
safety and supplying robust, integrated systems that quickly and easily deliver
the decision critical information required by clinicians. Furthermore, having
spent the 16 months since our last purchase developing an integrated business
platform into which we can rapidly consolidate future acquisitions, we expect
Scorpio to be both earnings enhancing and capable of stimulating further organic
growth within a relatively short period."

[currypasty] 05/10/2007 09:24

RNS Number:2135F
Ascribe plc
05 October 2007




Ascribe plc
(the "Company")

Holding in Company


The Company received notification on 4 October 2007 from Jade Direct
NZ Limited ("Jade") that on 4 October 2007 Jade no longer had a notifiable
interest in the Company

[currypasty] 04/9/2007 07:07

RNS Number:1932D
Ascribe plc
04 September 2007



Press Release 4 September 2007

Ascribe plc

("Ascribe" or "the Group")

Notice of Final Results


Ascribe plc ("AIM:ASP"), the health IT Group, will be announcing its Final
Results for the year ended 30 June 2007 on Wednesday 19 September 2007.

An analyst briefing given by Stephen Critchlow, Executive Chairman and Jeremy
Lee, Finance Director will be held at 9.30 am on Wednesday 19 September 2007 at
Abchurch Communications, 5th Floor, 100 Cannon Street, London, EC4N 6EU.

[peter the pieman] 22/8/2007 08:27

Check out the competitive bid situation between CSC and IBA for IOT. IBA's bid now values IOT at around £166m. For a defunct Lorenzo software product, no new customers for months and an admission by Connecting for Health that hospital trusts can go ahead and use local IT solutions, this is a big valuation and I think reflects the cash flow potential (post restructuring)of IOT's maintenance contracts.

The point though, is that the bid values IOT at nearly 4x the mkt cap of Ascribe. Of the two, it's not hard to see which one is misvalued..

[peter the pieman] 21/8/2007 12:11

What on earth does it mean "the price was engineered to let some large holders swap their stock about". This sort of statement shows amazing ignorance about the stock market and how institutional shareholders work - typical of these chatrooms.
Can I suggest you take a job in the City for a few months - best training ever for day trading. I can tell you for nothing that the probablity that any sell/buy or buy/buy institutions have colluded - and in doing so breaking the law and putting their lucrative businesses at risk - for a few thousand extra profit is zero.
The share will bounce back when the market makers have flushed out all potential sellers, creating a demand squeeze. With many sellers through their stop losses, this process is probably quite protracted. However, given the turnover recently, I'd guess the bounce isn't far away.